Xie Yalin, Liang JiZhen, Su Ning
Departmet of Oncology, Guangzhou Chest Hospital, Guangzhou 510095, China.E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2015 Mar;35(3):446-9.
To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.
Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib.
There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293).
There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.
比较厄洛替尼与吉非替尼一线治疗晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）患者的疗效。
将50例未经治疗的晚期EGFR突变阳性NSCLC患者随机分为吉非替尼组（n = 27）和厄洛替尼组（n = 23）。评估无进展生存期、客观缓解率和疾病控制率，以比较吉非替尼和厄洛替尼的疗效。
两组的客观缓解率（P = 0.711）和疾病控制率（P = 0.861）无显著差异。吉非替尼组和厄洛替尼组的无进展生存期分别为8.0个月和10.0个月。两种药物的疗效相似（P = 0.293）。
在一线治疗晚期EGFR突变阳性NSCLC患者中，吉非替尼和厄洛替尼之间无显著差异。
